𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetine

✍ Scribed by David V. Sheehan; Pratap R. Chokka; Renee E. Granger; Richard J. Walton; Joel Raskin; Doron Sagman

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
339 KB
Volume
26
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

Objective

This post hoc analysis of a multicenter, single‐arm, open‐label trial (the Attributes of Response in Depressed Patients Switched to Treatment with Duloxetine [ARDENT] study) assessed the relationship between functional improvement in the Sheehan Disability Scale (SDS) and clinical outcomes of mood, pain, and anxiety over 8 weeks after switching treatment to duloxetine in patients with major depressive disorder.

Methods

Analyses included all 195 patients who completed the study. Pearson's correlation and multivariate regression analyses were used to evaluate the relationship between change from baseline in SDS total score and 17‐item Hamilton Rating Scale for Depression (HAMD~17~) Maier score (mood), Brief Pain Inventory‐Short Form average pain score (pain), and Hamilton Anxiety Rating Scale total score (anxiety) at week 8.

Results

At week 8, change in SDS total score was positively correlated with change in mood (r = 0.49), anxiety (r = 0.44), and pain (r = 0.40). Multivariate linear regression coefficients for mood and pain were estimated at 1.21 (standard error [SE] = 0.184) and 1.16 (SE = 0.180), respectively (both p < 0.0001) compared with 0.02 (SE = 0.097; p = 0.82) for anxiety. Overall, 43% of patients achieved both HAMD~17~ and SDS total remission.

Conclusions

Functional improvement at 8 weeks was positively correlated with mood, pain, and anxiety in patients with major depressive disorder switched to duloxetine. Change in mood and pain exerted a relatively stronger joint effect on functioning than did anxiety in this patient population. Copyright © 2011 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Assessment of depressive symptoms and fu
Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol
✍ Tina Marie Myers Oakes; Adam L. Myers; Lauren B. Marangell; Jonna Ahl; Apurva Pr 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views

Objective Return of functional ability is a central goal in the treatment of major depressive disorder. We conducted two trials with the same protocol that was designed to assess functioning after 8 Weeks of treatment with duloxetine. Methods The a priori primary outcome was improvement in the Hamil

A double-blind, multicenter trial compar
A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder
✍ Lesley M. Arnold; Yili Lu; Leslie J. Crofford; Madelaine Wohlreich; Michael J. D 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views

## Abstract ## Objective To assess the efficacy and safety of duloxetine, a serotonin and norepinephrine reuptake inhibitor, in subjects with primary fibromyalgia, with or without current major depressive disorder. ## Methods This study was a randomized, double‐blind, placebo‐controlled trial co

Inverse correlation between clinical res
Inverse correlation between clinical response to paroxetine and plasma drug concentration in patients with major depressive disorders
✍ Norio Yasui-Furukori; Taku Nakagami; Ayako Kaneda; Yoshimasa Inoue; Akihito Suzu 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB 👁 1 views

## Objective There are few data concerning a clear relationship between the clinical effect of paroxetine and plasma drug concentrations, although therapeutic ranges have been established for some tricyclic antidepressants. ## Methods In this study, 120 patients with major depressive disorders we